naftopidil has been researched along with Urinary Retention in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kojima, Y; Miyake, O; Oda, M; Okuyama, A; Tsujihata, M; Uchida, K; Yoshimura, K | 1 |
| Hanazawa, K; Honda, S; Kawachi, Y; Koizumi, K; Maruyama, O; Noto, K; Saitoh, T; Sugimura, S; Sugiyama, Y; Yamashita, R | 1 |
1 trial(s) available for naftopidil and Urinary Retention
| Article | Year |
|---|---|
Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Benzilates; Cholinergic Antagonists; Drug Therapy, Combination; Follow-Up Studies; Humans; Male; Mandelic Acids; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Treatment Outcome; Urinary Retention; Urodynamics | 2006 |
1 other study(ies) available for naftopidil and Urinary Retention
| Article | Year |
|---|---|
[The clinical efficacy and safety of naftopidil 75 mg on benign prostatic hyperplasia patients with moderate or severe urinary disturbance].
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Urinary Retention | 2009 |